Last reviewed · How we verify
Adaptive Dose-Escalated Multi-modality Image-guided RadiothErapy (ADMIRE)
Patients with primary head and neck squamous cell carcinoma (HNSCC) planned for treatment with radiotherapy with or without chemotherapy in curative setting will be treated with an adaptive radiotherapy scheme. An FDG-PET/CT scan for re-delineation and re-planning will be made at the end of the second and fourth of week of radiotherapy. The non-responding part of the tumor on FDG-PET will receive a mild dose-escalation. Depending on the metabolic response, the entire tumor will receive 70 Gy or the residual FDG-avid area will receive 74 or 78 Gy.
Details
| Lead sponsor | The Netherlands Cancer Institute |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 20 |
| Start date | Thu Dec 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Apr 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Head and Neck Cancer
Interventions
- Adaptive dose-Escalated multi-modality image-guided radiotherapy
Countries
Netherlands